65,437 trials
Head Trauma · Craniocerebral Injuries · Crushing Skull Injury
Primary: Sensitivity of InfraScanner 2000 TM to Detect Any Size Hematoma at the Patient Level — 85.6 percentage
Osteoporosis in Men
Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Month 12 — 1.2; 12.1 percent change — p=< 0.0001
Alcoholism
Primary: Startle Potentiation During Stress Reactivity Task. — 45.7; 40.1; 33.2; 25.2 startle potentiation (μV)
Psoriasis
Primary: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A) — 47.4; 72.4 percentage of…
Epilepsy
Primary: Time to Next Seizure (Per Clinical Observation With Electroencephalogram [EEG] Confirmation) or Rescue Medication — NA; NA; NA hours
Wheezing · Asthma · Allergy
Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38
Glabellar Lines
Primary: The Percentage of Responders at Day 29 Cycle 1 as Measured by Investigator's Live Assessment (ILA) of Glabellar Lines at Maximum Frown: DB Period — 81.6; 0.8 Adjusted…
Masseter Muscle Hypertrophy
Primary: Change From Baseline in Lower Facial Volume Using VECTRA 3D Images — -8.20; -7.41; -6.84; -4.40 cubic centimeter (cm^3) — p=< 0.001
Cervical Lesions
Primary: Retention of Restorations — 38; 38; 37; 37 Non-carious cervical lesions
Non-small Cell Lung Cancer
Primary: Change From Baseline in Tumor Size to the End of Cycle 2 — 1.06; 1.01 Log Ratio of Tumor Size — p=0.284
Airway Control · Anesthesia · Intubation
Primary: SOFA Score — 6.5; 7 units on a scale
Preterm Birth · Child Development
Primary: Erythrocyte Fatty Acid Levels — -2.1; 0.6; 2.0; -0.2 nmol/mL — p=<0.001
Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
Primary: Overall Complete Remission Rate at Day 28 After CART-19 Therapy — 8; 10; 6; 6 Participants
Autism Spectrum Disorders
Primary: Change From Baseline in Parent Rated Social Responsiveness Scale, 2nd Edition (SRS-2) T-Score After Treatment. — 10.8; 17.6 units on a scale
Advanced, Persistent, or Recurrent Endometrial Cancer
Primary: Frequency of Response — 9; 8 Number of participants